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Abstract
We performed fine-mapping of 39 established type 2 diabetes (T2D) loci in 27,206 cases and 
57,574 controls of European ancestry. We identified 49 distinct association signals at these loci, 
including five mapping in/near KCNQ1. “Credible sets” of variants most likely to drive each 
distinct signal mapped predominantly to non-coding sequence, implying that T2D association is 
mediated through gene regulation. Credible set variants were enriched for overlap with FOXA2 
chromatin immunoprecipitation binding sites in human islet and liver cells, including at MTNR1B, 
where fine-mapping implicated rs10830963 as driving T2D association. We confirmed that this 
T2D-risk allele increases FOXA2-bound enhancer activity in islet- and liver-derived cells. We 
observed allele-specific differences in NEUROD1 binding in islet-derived cells, consistent with 
evidence that the T2D-risk allele increases islet MTNR1B expression. Our study demonstrates 
how integration of genetic and genomic information can define molecular mechanisms through 
which variants underlying association signals exert their effects on disease.
INTRODUCTION
Genome-wide association studies (GWAS) of common variants, defined by minor allele 
frequency (MAF) ≥5%, have been successful in identifying loci contributing to type 2 
diabetes (T2D) susceptibility1-5. GWAS loci are typically represented by a “lead” SNP with 
the strongest signal of association in the region. However, lead SNPs may not directly 
impact disease susceptibility, but instead be proxies for causal variants because of linkage 
disequilibrium (LD). Interpretation may be further complicated by the presence of more than 
one causal variant at a locus, possibly acting through the joint effects of alleles on the same 
haplotype. This complex genetic architecture would result in multiple “distinct” association 
signals at the same locus, which can only be delineated, statistically, through conditional 
analyses.
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With the exception loci where the lead SNPs are protein altering variants, including 
PPARG6, KCNJ11-ABCC87, SLC30A88, and GCKR9, the mechanisms by which associated 
alleles influence T2D susceptibility are largely unknown. At other loci, direct biological 
interpretation of the effect of genetic variation on T2D is more challenging because the 
association signals mostly map to non-coding sequence. While recent reports have 
demonstrated a relationship between T2D-associated variants and transcriptional enhancer 
activity, particularly in human pancreatic islets, liver cells, adipose tissue, and muscle10-14, 
the DNA-binding proteins through which these effects are mediated remain obscure. 
Localisation of non-coding causal variants may highlight the specific regulatory elements 
they perturb, and potentially the genes through which they operate, providing valuable 
insights into the pathophysiological basis of T2D susceptibility at GWAS loci.
To improve the localisation of potential causal variants for T2D, and characterise the 
mechanisms through which they alter disease risk, we performed comprehensive fine-
mapping of 39 established loci through high-density imputation into 27,206 cases and 
57,574 controls from 23 studies of European ancestry, genotyped with the Metabochip15 
(Supplementary Tables 1 and 2). Within each locus, we aimed to: (i) evaluate the evidence 
for multiple distinct association signals through conditional analyses; (ii) undertake fine-
mapping by defining credible sets of variants that account for ≥99% of the probability of 
driving each distinct association signal; and (iii) interrogate credible sets for functional and 
regulatory annotation to provide insight into the mechanisms through which variants driving 
association signals influence disease risk.
RESULTS
Imputation into Metabochip fine-mapping regions
The Metabochip includes high-density coverage of 257 “fine-mapping regions” that have 
been previously associated with 23 metabolic, cardiovascular, and anthropometric traits15. 
SNPs in these regions were selected using reference data from the HapMap16 and the 1000 
Genomes (1000G) Project17. At design, 27 T2D susceptibility loci were selected for fine-
mapping. However, subsequent T2D GWAS efforts have identified additional loci that 
overlap 12 further fine-mapping regions that were initially selected for other traits 
(Supplementary Table 3). To enhance coverage of variation in the fine-mapping regions, we 
undertook imputation into the Metabochip scaffold up to the 1000G phase 1 integrated 
reference panel (March 2012 release)18, including multi-ethnic haplotypes to reduce error 
rates19 (Online Methods).
The quality of imputation was variable across studies, particularly for MAF<5% variants, 
and dependent on the scaffold sample size (Supplementary Table 4). We defined variants to 
be “well-imputed” at widely-used thresholds20 of IMPUTEv221 info≥0.4 or minimac22 
r2≥0.3 in at least 80% of the total effective sample size (Neff≥59,122) across studies. With 
this definition, 99.4% and 89.0%, respectively, of common and low-frequency 
(0.5%≤MAF<5%) variants in 1000G European ancestry haplotypes were well imputed, and 
therefore retained for downstream association analyses. Within studies, imputation quality 
was consistent across loci, despite the differential priority of fine-mapping regions and their 
coverage of variation at design (Supplementary Table 5). 1000G imputation into the 
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Metabochip scaffold thus provides near complete coverage of common and low-frequency 
variation across the 39 T2D susceptibility loci, and supports direct interrogation of the 
majority of variants with MAF≥0.5% in European ancestry populations.
Distinct association signals at T2D susceptibility loci
The first step in fine-mapping GWAS loci is to delineate distinct association signals arising 
from multiple causal variants in the same region, which can efficiently be achieved through 
approximate conditioning with GCTA23. Within each T2D fine-mapping region, we 
identified distinct signals attaining “locus-wide” significance (represented by an index 
variant with pJ<10−5 in the joint association model) by applying GCTA in two stages 
(Online Methods). First, we selected index variants on the basis of fixed-effects meta-
analysis across Metabochip studies. Second, we performed in silico replication of the index 
variants in a validation meta-analysis of an additional 19,662 T2D cases and 115,140 
controls from 10 GWAS of European ancestry (Supplementary Tables 1, 2, and 6). Finally, 
because GCTA is only an approximation, we confirmed the association of each index variant 
through exact conditional analysis across Metabochip studies (Online Methods, 
Supplementary Table 7).
The most dramatic delineation of distinct association signals was observed for the region 
flanking KCNQ1, where five non-coding index variants attained locus-wide significance 
(Table 1, Supplementary Figure 1). Distinct association signals represented by three of the 
index variants have been reported in previous GWAS of European4 and East Asian24 
ancestry: rs74046911 (pJ=3.6×10−26, r2=0.98 with East Asian lead SNP, rs2237897) and 
rs2237895 (pJ=2.1×10−9, r2=0.75 with one European lead SNP, rs163184), both of which 
map to a <50kb intronic recombination interval of KCNQ1; and chr11:2692322:D 
(pJ=7.2×10−16, r2=0.59 with second European lead SNP, rs231361), which resides in the 
KCNQ1OT1 transcript that controls regional imprinting25. The remaining two distinct 
association signals at this locus are novel. The first, indexed by rs458069 (pJ=3.2×10−6), 
maps to the same <50kb recombination interval as rs74046911 and rs2237895, but is in only 
weak LD with both (r2=0.02 and r2=0.25, respectively). The second, indexed by rs2283220 
(pJ=2.2×10−7), resides in a neighbouring intron of KCNQ1, outside of the <50kb 
recombination interval (Supplementary Figure 1).
At the HNF1A locus, we observed three distinct association signals (Table 1, Supplementary 
Figure 2), represented by index variants that are in only weak LD with the previously 
reported lead GWAS SNP, rs12427353. They include two non-synonymous variants, 
rs1169288 (pJ=4.4×10−14, r2=0.09, HNF1A p.I27L) and rs1800574 (pJ=4.2×10−10, r2=0.01, 
HNF1A p.A98V), and one inter-genic SNP, chr12:121440833:D (pJ=2.9×10−10, r2=0.19).
We also observed four loci with two distinct association signals (CDKN2A-B, DGKB, 
MC4R and GIPR), each represented by non-coding index variants (Table 1, Supplementary 
Figure 3). The index variants at the CDKN2A-B locus represent the known T2D haplotype 
association signal mapping to a 12kb inter-genic recombination interval26-28. Previous 
European ancestry GWAS meta-analyses4 have highlighted a potential distinct association 
signal, located upstream of the recombination interval in the non-coding CDKN2B-AS1 
(ANRIL) transcript. However, our conditional analyses indicate that the association in this 
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region can be fully explained by the two index SNPs in the recombination interval, which 
when considered together, fully extinguish the CDKN2B-AS1 signal (Supplementary Figure 
4). The index variants at DGKB and MC4R also confirm previously reported distinct 
association signals at these loci in European ancestry GWAS meta-analyses4. At the GIPR 
locus, the two index variants (rs2238689, pJ=8.3×10−16; rs4399645, pJ=1.4×10−8) are not in 
strong LD with the previously reported4 lead SNP (rs8108269; r2=0.43 with rs2238689, 
r2=0.00 with rs4399645), but together can better explain the T2D association signal in this 
region.
Finally, we observed a novel distinct association signal at the HNF4A locus, represented by 
the coding index variant rs1800961 (pJ=1.4×10−9, HNF4A p.T139I, referred to as p.T130I in 
some previous studies29). Unfortunately, this fine-mapping region was included on 
Metabochip for high-density lipoprotein cholesterol15,30 (Supplementary Table 3), and does 
not include the previously reported4 lead T2D SNP at this locus, rs4812829, precluding 
conditional analyses in these data. However, rs4812829 is not in LD with our index variant 
(r2=0.02), suggesting that there are at least two distinct T2D association signals at the 
HNF4A locus.
Of the 49 distinct association signals achieving locus-wide significance across T2D loci 
represented on Metabochip (five at KCNQ1, three at HNF1A, two each at CDKN2A-B, 
DGKB, MC4R and GIPR, and one each at the remainder), only three index variants are not 
common (Supplementary Table 6, Supplementary Figure 5): rs1800574 (MAF=2.2%, 
OR=1.21) for one signal at the HNF1A locus; rs1800961 (MAF=3.9%, OR=1.16) at the 
HNF4A locus; and rs17066842 (MAF=4.8%, OR=1.12) for one signal at the MC4R locus.
Localising variants driving T2D association signals
We used statistical evidence of association from the meta-analysis of Metabochip studies to 
construct 99% “credible sets” of variants28 that are most likely to drive the 49 distinct 
signals (Online Methods, Supplementary Table 8, Supplementary Figure 6). For ten distinct 
association signals, mapping to nine loci, the 99% credible set included no more than ten 
variants (Table 2, Supplementary Table 9). The greatest refinement was observed at the 
MTNR1B locus, where the credible set included only the index variant, rs10830963, 
accounting for more than 99.8% of the posterior probability of driving the association signal 
(πC). Small credible sets were also observed for the association at TCF7L2 (three variants, 
indexed by rs7903146, mapping to 4.3kb), and one signal at KCNQ1 (three variants, indexed 
by rs74046911, mapping to just 200bp). The 99% credible sets for both distinct association 
signals at CDKN2A-B together included just 11 variants in total, and map to less than 2kb.
We performed functional annotation of credible variants to search for evidence that 
association signals are driven by coding alleles. Across the 49 signals, only nine coding 
variants attained πC>1% (Supplementary Table 10), including six previously reported non-
synonymous T2D-risk alleles at PPARG6, KCNJ11-ABCC87,31,32, SLC30A88,33, and 
GCKR9,34. The remaining three coding alleles were the index variants for association 
signals mapping to HNF4A (p.T139I, rs1800961, πC=97.4%) and HNF1A (p.I27L, 
rs1169288, πC=75.5%; p.A98V, rs1800574, πC=34.0%). Our findings are supported by 
earlier studies, which reported nominal evidence for association of these three coding 
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variants with T2D and defects in insulin secretion in vivo, and demonstrated reduced 
transcriptional activity of HNF1A target genes using in vitro assays29,35. These data provide 
strong evidence that HNF4A and HNF1A are T2D effector transcripts at these loci, a view 
further supported by the known impact of rare, loss of function mutations in these genes on 
maturity onset diabetes of the young36,37. Given the near complete coverage of common and 
low-frequency variants in fine-mapping regions after 1000G imputation, it is unlikely that 
additional distinct signals in established T2D susceptibility loci represented on the 
Metabochip are driven by coding variation with MAF≥0.5%, confirming reports that these 
associations are most likely to be mediated by effects on gene regulation10,13,14,38.
Regulatory mechanisms underlying T2D association signals
We sought to understand the regulatory mechanisms through which variants at the 39 
established T2D susceptibility loci influence disease by intersecting the 99% credible sets 
for each distinct association signal with chromatin immunoprecipitation sequence (ChIP-
seq) data for 165 transcription factors, chromatin state maps from 12 cell types, and long 
non-coding RNA transcripts from 25 cell types (Online Methods, Supplementary Table 11). 
We applied an enrichment procedure that compared the mean posterior probability of driving 
the association signal for credible set variants directly overlapping sites for each regulatory 
annotation with a null distribution obtained from randomly shifted site locations within 
100kb in either direction.
We first applied this procedure to chromatin state and non-coding RNA elements using the 
19,266 credible set variants for all 49 distinct association signals (Supplementary Figure 7). 
Using a Bonferroni correction for the 37 tested cell type annotations (p<0.0014), variants in 
pancreatic islet enhancer elements14 had significantly higher posterior probability of driving 
association signals than that expected from the null distribution (1.97-fold, p=0.00022). We 
also observed nominal evidence for enrichment of the posterior probability of driving 
association signals among variants in human islet and hepatocellular carcinoma (HepG2) 
promoters10,14 (p=0.0052 and p=0.0064, respectively). However, there was no 
corresponding enrichment of variants in regulatory elements for other cell types or in non-
coding transcripts. These results are consistent with previous studies supporting a 
contribution of regulatory enhancer and promoter variants to T2D susceptibility in specific 
cell types11-14.
We next sought to gain insight into the transcription factors these regulatory variants perturb, 
and applied the same procedure to ChIP-seq binding data for 165 proteins (Figure 1, 
Supplementary Figure 8). Using a Bonferroni correction for the 165 tested proteins 
(p<0.00030), the 89 credible set variants overlapping 57 FOXA2 ChIP-seq binding sites, 
assayed in human HepG210 and islet14 cells, had significantly higher posterior probability of 
driving association signals than expected from the null distribution (8.24-fold, p=0.00028). 
The enrichment of FOXA2 ChIP-seq sites was exclusive to those shared with at least one 
other factor (9.18-fold, p=0.00028) compared to those that were not (1.12-fold, p=0.11). 
FOXA2 enrichment was also more pronounced among sites identified in pancreatic islets 
(15.43-fold, p=0.00045) than in HepG2 cells (4.55-fold, p=0.011). To exclude the possibility 
that this enrichment in HepG2 cells was driven by artefacts caused by a cultured cell line, we 
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compared FOXA2 HepG2 sites to those previously assayed in primary liver39. We observed 
significant intersection of the HepG2 and liver FOXA2 sites that overlapped credible set 
variants (p=1.5×10−9). Consequently, we detected similar FOXA2 enrichment among sites 
detected in liver (3.63-fold, p=0.061) to that observed in HepG2 cells. We also compared 
FOXA2 ChIP-seq sites, genome-wide, from liver, HepG2 and islet cells (Supplementary 
Figure 9). The number of sites varied across cell types (8,023 for liver, 40,866 for HepG2, 
and 27,291 for islets), which is likely due, in part, to technical differences including 
sequencing platform, depth and read length. However, the intersection of FOXA2 sites 
between each pair of cell types was highly significant (p<2.2×10−16).
Given the preponderance of T2D-associated variants for islet enhancers, we next tested to 
what extent FOXA2 enrichment is driven by co-localisation with these genomic features14. 
Variants in FOXA2-bound sites were not enriched for posterior probability of driving 
association signals after removing enhancer sites (0.36-fold, p=0.69). Conversely, variants in 
islet enhancers remained nominally enriched when removing FOXA2 sites (1.65-fold, 
p=0.014). These results suggest that FOXA2 binding assayed by ChIP-seq, at a subset of 
enhancer element locations that are often shared by other proteins, is a genomic marker of 
variants with an increased posterior probability of driving T2D association signals.
Having demonstrated global over-representation for FOXA2 ChIP-seq binding by 
considering all loci simultaneously, we applied the same procedure to the 99% credible sets 
of each distinct association signal, separately, to identify those with the strongest evidence 
for local enrichment (Figure 1). We observed over-representation of credible set variants in 
islet or HepG2 FOXA2 sites for 19 association signals, 15 of which attained nominal 
significance (p<0.05). A total of 41 credible set variants at these 19 distinct association 
signals overlap a FOXA2 ChIP-seq site in at least one of the two cell types (Supplementary 
Table 12). Of these, 12 variants were predicted to disrupt de novo recognition motifs (for 
FOXA2 and other factors) that were enriched in FOXA2-bound sequence (Table 3, 
Supplementary Table 13). The mean posterior probability of driving the association (πC) for 
these 12 variants was 22.0% on the basis of genetic fine-mapping (Figure 1), more than four 
times greater than for those in FOXA2 ChIP-seq sites that were not motif-disrupting at the 
same signals (mean πC of 5.2%, p=0.024). Furthermore, 11 of these 12 variants also 
overlapped an enhancer element in islets (9 variants) or HepG2 cells (6 variants), indicating 
that they are in transcriptionally active regions (Table 3). They include two variants with 
experimentally validated differences in regulatory activity: rs7903146 (πC=77.6%) at 
TCF7L240 and rs11257655 (πC=21.1%) at CDC12341. They also include rs10830963, the 
index variant at the MTNR1B locus, which accounts for 99.8% of the posterior probability 
of driving the association signal on the basis of genetic fine-mapping. These results suggest 
that FOXA2 binding patterns can be used to highlight specific variants that are potentially 
causal for T2D susceptibility through altered regulatory binding.
Altered regulatory activity of the MTNR1B credible variant
To demonstrate how local enrichment of FOXA2 binding can be used to highlight regulatory 
mechanisms through which credible variants might impact T2D susceptibility, we focussed 
on the MTNR1B locus. Variants mapping to this region have amongst the strongest known 
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effects on both T2D risk6 and fasting plasma glucose concentration42, and physiological data 
indicate an impact of MTNR1B on both insulin secretion and insulin action43. The lone 
credible variant at MTNR1B, rs10830963, overlaps a FOXA2 ChIP-seq binding site, and the 
risk allele, G, is predicted to create a recognition motif that matches the consensus sequence 
of NEUROD1 and several other factors (Figure 2, Supplementary Table 13). We tested in 
silico predictions of protein binding at rs10830963 via electrophoretic mobility shift assay 
(EMSA) with 25bp probe fragments surrounding each allele in human pancreatic islet beta-
cell (EndoC-βH1)44 or human liver HepG2 cell extracts. We observed allele-specific binding 
with extracts from both cell lines (Figure 2, Supplementary Figure 10).
To determine the specific protein(s) bound at each allele, we then performed supershift 
experiments using antibodies directed against NEUROD1, FOXA2, and three other factors 
(TAL1, PTF1A, and YY1), whose consensus binding sequences resemble the recognition 
motif (Online Methods). We observed a shift in the presence of the NEUROD1 antibody on 
the risk allele in EndoC-βH1 extracts, which could be competed away by an excess of 
unlabelled NEUROD1 consensus sequence probe (Figure 2). None of the tested antibodies 
(including NEUROD1) shifted the risk allele band in HepG2 cell extracts (Supplementary 
Figure 10). These results demonstrate that, in vitro, the risk allele of rs10830963 
preferentially binds NEUROD1 in islet-derived cells, and binds a protein not identified from 
known recognition motifs in liver-derived cells.
To relate allelic differences in protein binding to genomic activity at this site, we cloned a 
224bp region surrounding rs10830963 into a luciferase reporter vector containing a minimal 
promoter, and tested its enhancer activity in EndoC-βH1 and HepG2 cell lines. Consistent 
with in silico predictions, we observed a significant (p<0.05) increase in luciferase 
expression on the risk allele compared to the protective allele in both cell lines (Figure 2). 
Furthermore, RNA-seq data reported from human islets have linked the T2D risk allele of 
rs10830963 to increased expression of MTNR1B45,46. Taken together, these results suggest 
that the G allele of rs10830963 increases T2D risk through increased FOXA2-bound 
enhancer activity, potentially mediated through NEUROD1 binding in islets, and 
consequently higher expression of MTNR1B.
Candidate effector genes at FOXA2 enriched T2D signals
We hypothesised that the locus-specific effects of murine transcription factor knockout 
models would mimic patterns of binding enrichment at human disease loci. We thus 
attempted to relate FOXA2 binding at the 19 FOXA2-enriched association signals (Figure 1) 
to target effector genes using previously reported pancreatic islet expression profiles from 
wild-type and Foxa1/2-null mice47 (Online Methods). Syntenic genes mapping within 500kb 
of the credible set at the 19 FOXA2-enriched signals were significantly down-regulated 
(45.2% decrease) in Foxa1/2 knockout mice (Supplementary Figure 11) compared to those 
genome-wide (0.021% increase, p=0.012), whilst those mapping within 500kb of the other 
30 T2D association signals were not (2.25% decrease, p=0.20). We observed a consistent 
down-regulation (39.6% decrease) when considering only those genes mapping closest to 
each FOXA2-enriched signal, compared to those genome-wide (0.021% increase, 
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p=0.0021). Thus, data related to altered gene expression in Foxa1/2 knockout mice support 
patterns of FOXA2 binding site enrichment in humans.
We next identified specific genes at the 19 FOXA2-enriched association signals that were 
down-regulated in Foxa1/2 knockout mice, which might represent effector transcripts for 
these loci (Supplementary Table 14). Several of these genes have been previously implicated 
as likely effector transcripts in humans, including TCF7L248,49 (57% decrease), KCNJ117,50 
(38% decrease), and SLC30A851 (135% decrease). These data also implicate novel 
candidate effector genes at FOXA2-enriched association signals (Supplementary Table 14). 
For example, in Foxa1/2 knockout mice, there is a marked down-regulation of Reg4 
(1,415% decrease), which maps to a syntenic region at the FOXA2-enriched NOTCH2 
GWAS locus, highlighting REG4 as a likely effector transcript in humans. Additional 
examples of candidate effector genes include IGF2 at the KCNQ1 locus (135% decrease), 
and CAMK1D at the CDC123 locus (81% decrease). Together, these results provide 
additional support for the importance of FOXA2 binding at a subset of T2D susceptibility 
loci, and further highlight specific genes through which regulatory variants in these regions 
may operate.
DISCUSSION
We have undertaken comprehensive fine-mapping of 39 established T2D susceptibility loci 
in 27,206 cases and 57,574 controls of European ancestry, and have demonstrated that 
multiple distinct association signals in these regions is a common phenomenon. Index 
variants for just three of the 49 distinct association signals are not common, despite near 
complete coverage of variation with MAF≥0.5% in fine-mapping regions after 1000G 
imputation. Although we cannot evaluate the impact of rare variation (MAF<0.5%) in 
established T2D susceptibility loci without large-scale re-sequencing, our data strongly 
argue against a role for low-frequency variants of large effect via synthetic association52. We 
have demonstrated that seven distinct association signals, mapping to six T2D susceptibility 
loci represented on the Metabochip, are likely to be driven by coding alleles, including novel 
index variants mapping to HNF1A and HNF4A. Outside of these regions, our fine-mapping 
confirms previous reports that T2D association signals are primarily driven by non-coding 
alleles, with effects that are mediated through gene regulation10,13,14,38.
We have demonstrated, by genomic annotation and functional assays, that FOXA2 binding 
assayed by ChIP-seq can be used to pinpoint candidate causal regulatory elements, 
providing routes to understanding the biology of specific T2D susceptibility loci. These 
elements highlight variants and effector transcripts through which association signals are 
mediated, via altered binding of either FOXA2, directly, or another transcription factor. For 
example, at the MTNR1B locus, the risk allele of the lone credible variant, rs10830963, 
which drives the T2D association signal, preferentially binds NEUROD1 in islet-derived 
cells in vitro, and increases FOXA2-bound enhancer activity in human islet and liver-derived 
cells. These data are consistent with previous reports correlating the risk allele with higher 
MTNR1B expression45,46, and not loss of function53, and suggest altered NEUROD1 
binding in islets contributes to T2D susceptibility at this locus. Further experiments will be 
required to establish that our in vitro findings regarding NEUROD1 binding can be 
Gaulton et al. Page 8
Nat Genet. Author manuscript; available in PMC 2016 May 18.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
confirmed in vivo. However, our attempts to perform ChIP-Seq in primary islet samples of 
the defined MTNR1B genotype were repeatedly unsuccessful, owing to a lack of a suitable 
NEUROD1 antibody. These studies are further complicated by the limited availability of 
primary human islets, and the slow division rate of human islet derived cell-lines is an 
impediment to the implementation of genome-editing technologies.
FOXA2 is a pioneer factor that binds native chromatin and bookmarks genomic regions for 
transcriptional activity54, and is involved in pancreatic and hepatic development55,56. 
FOXA2 is also expressed in other T2D-relevant cell types, such as adipocytes. Future studies 
will be required to elucidate the extent to which FOXA2 binding events across cell types 
influence disease risk. Foxa2 null mice have impaired insulin secretion47, and common 
variants at the FOXA2 locus are associated with fasting plasma glucose concentrations42,57. 
Our findings are thus consistent with the involvement of FOXA2 in maintaining normal 
glucose homeostasis. Common T2D-associated variants at FOXA2 have also been reported 
in South Asians58, although they do not attain genome-wide significance in the largest 
GWAS for the disease from multiple ancestry groups1-5, and therefore require further 
replication. Enrichment of FOXA2 binding has also been reported within genomic intervals 
containing GWAS signals for endocrine, neuropsychiatric, cardiovascular and cancer 
traits59. Our study has the advantage that we consider only those FOXA2 sites that directly 
overlap variants that drive association signals by first fine-mapping GWAS loci, thereby 
providing more targeted credible sets for functional enrichment. Nevertheless, the results of 
these studies, taken together, suggest a possible role for FOXA2 across a broad spectrum of 
complex human phenotypes.
In conclusion, we have highlighted that FOXA2 binding patterns can be used to inform 
future hypothesis-driven investigation of the variants, genes, and molecular mechanisms 
underlying T2D association signals mapping to non-coding sequence. Continued 
identification of the effector transcripts at these non-coding association signals will require 
the use of expression QTL and knockout models, in combination with high-throughput 
experimental data derived from chromatin conformation capture techniques, such as 
Capture-C. Our findings support the use of transcription factor binding events as a means to 
partition susceptibility loci, potentially residing in distinct pathways, within disease-relevant 
cell types. Finally, our study demonstrates the utility of fine-mapping through integration of 
genetic and genomic information from relevant tissues and cellular models to elucidate the 
pathophysiology of complex human diseases, thus offering a promising avenue for 
translation of GWAS findings for clinical utility.
ONLINE METHODS
Ethics statement
All human research was approved by the relevant institutional review boards, and conducted 
according to the Declaration of Helsinki. All participants provided written informed consent.
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Metabochip imputation and association analysis
We considered a total of 27,206 T2D cases and 57,574 controls from 23 studies from 
populations of European ancestry (Supplementary Table 1), all genotyped with the 
Metabochip. Sample and variant quality control was performed within each study 
(Supplementary Table 2). To improve the quality of the genotype scaffold in each study, 
variants were subsequently removed if: (i) allele frequencies differed from those for 
European ancestry haplotypes from the 1000 Genomes Project Consortium phase 1 
integrated reference panel (March 2012 release)18 by more than 20%; AT/GC variants had 
MAF>40% because of potential undetected errors in strand alignment; or (iii) MAF<1% 
because of difficulties in calling rare variants. Each scaffold was then imputed up to up to 
the phase 1 integrated reference panel (all ancestries, March 2012 release) from the 1000 
Genomes Project Consortium18, using IMPUTEv221 or minimac22. Within each study, well-
imputed variants (IMPUTEv221 info>0.4 or minimac22 r2>0.3) were tested for T2D 
association under an additive model after adjustment for study-specific covariates 
(Supplementary Table 2), including principal components to adjust for population structure. 
Association summary statistics for each variant for each study were corrected for residual 
population structure using the genomic control inflation factor60 obtained from 3,598 
independent (r2<0.05) QT-interval variants, which were not expected to be associated with 
T2D4 (Supplementary Table 2). We then combined association summary statistics for each 
variant across studies via fixed-effects inverse-variance weighted meta-analysis. The results 
of the meta-analysis were subsequently corrected by a second round of QT-interval genomic 
control (λQT=1.18) to account for structure between studies. Variants were excluded from 
downstream analyses if they were reported in less than 80% of the total effective sample 
size, defined as Neff = 4×Ncases×Ncontrols/(Ncases+Ncontrols), thus removing those that were 
not well imputed in the majority of studies.
Identification of distinct association signals in established GWAS loci
We used GCTA23 to select index variants in each of the 39 established loci represented on 
Metabochip with nominal evidence of association (pJ<0.001) with T2D in an approximate 
joint regression model. The GCTA model made use of: (i) summary statistics from the fixed-
effects meta-analysis Metabochip studies; and (ii) genotype data for 3,298 T2D cases and 
3,708 controls of UK ancestry from GoDARTS as a reference for LD across each fine-
mapping region. For comparison, we also obtained association summary statistics for the 
selected index variants from the GCTA joint regression model on the basis of genotype data 
from an alternative reference consisting of 4,435 T2D cases and 5,757 controls of Finnish 
ancestry from FUSION (Supplementary Table 15, Supplementary Figure 12). Selected index 
variants were then carried forward for in silico follow-up in validation meta-analysis.
The validation meta-analysis consisted of 19,662 T2D cases and 115,140 controls from 10 
GWAS from populations of European ancestry, genotyped with a range of genome-wide 
arrays (Supplementary Table 1). Sample and variant quality control was performed within 
each study (Supplementary Table 2). Each scaffold was then imputed up to the phase 1 
integrated reference panel (all ancestries, March 2012 release) from the 1000 Genomes 
Project Consortium18, using IMPUTEv221 or minimac22. Within each study, well-imputed 
variants (IMPUTEv221 info≥0.4 or minimac22 r2≥0.3) were tested for T2D association under 
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an additive model after adjustment for study-specific covariates (Supplementary Table 2), 
including principal components to adjust for population structure. Association summary 
statistics for each variant for each study were corrected for residual population structure 
using the genomic control inflation factor60 (Supplementary Table 2). We then combined 
association summary statistics for each variant across studies via fixed-effects inverse-
variance weighted meta-analysis.
Association summary statistics for the selected index variants from the Metabochip and 
validation meta-analyses were next combined via fixed-effects inverse-variance weighted 
meta-analysis. In each of the 39 established loci represented on Metabochip, GCTA23 was 
used to select index variants with locus-wide evidence of association (pJ<10−5) in the 
approximate joint regression model on the basis of: (i) summary statistics from the 
combined meta-analysis; and (ii) genotype data for 3,298 T2D cases and 3,708 controls from 
GoDARTS as a reference for LD across each fine-mapping region.
For established loci with multiple index variants selected at locus-wide significance from the 
GCTA approximate joint regression model in combined meta-analysis, we performed exact 
conditioning within each Metabochip study (Supplementary Table 7). To obtain the 
association signal attributed to a specific index variant, high-quality variants (IMPUTEv221 
info>0.4 or minimac22 r2>0.3) were tested for T2D association under an additive model after 
adjustment for study-specific covariates (Supplementary Table 2) and genotypes at other 
selected index variants in the fine-mapping region. Association summary statistics for each 
study were corrected for residual population structure using the QT interval genomic control 
inflation factor obtained in the Metabochip meta-analysis. For each association signal, 
summary statistics for each variant were then combined across discovery studies via fixed-
effects inverse-variance meta-analysis, and subsequently corrected by a second round of QT-
interval genomic control (λQT=1.18).
Credible set construction
In an ideal fine-mapping experiment, we would calculate the posterior probability of driving 
each distinct association signal for all variants mapping to a locus. However, the posterior 
probability is determined by the association signal effect size of the variant and the 
corresponding standard error, which is also impacted by the quality of imputation across 
studies, amongst other factors. To minimise the impact of imputation quality on fine-
mapping, we therefore retained only those variants that were directly typed and/or well 
imputed in at least 80% of the total effective sample size. Assuming that the variant driving 
an association signal meets these quality criteria, the probability that it would be contained 
within the 99% credible set would be ~0.99.
For each distinct signal, we first calculated the posterior probability, πCj, that the jth variant 
is driving the association, given by
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where the summation is over all retained variants in the fine-mapping region. In this 
expression, Λj is the approximate Bayes’ factor61 for the jth variant, given by
where βj and Vj denote the estimated allelic effect (log-OR) and corresponding variance 
from the meta-analysis across Metabochip studies. In loci with multiple distinct signals of 
association, results are presented from exact conditional meta-analysis after adjusting for all 
other index variants in the fine-mapping region. In loci with a single association signal, 
results are presented from unconditional meta-analysis. The parameter ω denotes the prior 
variance in allelic effects, taken here to be 0.0461. The 99% credible set29 for each signal 
was then constructed by: (i) ranking all variants according to their Bayes’ factor, Λj; and (ii) 
including ranked variants until their cumulative posterior probability of driving the 
association attained or exceeded 0.99.
Genomic annotation data and enrichment analyses
We obtained genomic annotation data for transcription factor binding sites (TFBS) assayed 
through ChIP experiments from multiple sources. We used sites from the ENCODE Project 
Consortium10 for 161 proteins available from the UCSC human genome browser. We also 
obtained raw ChIP and input sequence data for additional factors assayed in primary 
pancreatic islets14. We then processed these additional factors using protocols employed by 
the ENCODE Project Consortium10. First, sequence reads were aligned to the human 
genome (hg19) using BWA62 with sex-specific references, and were then converted to BAM 
files using SAMtools63 after removing duplicate and non-uniquely mapped reads. Binding 
sites were called from reads of each replicate, as well as reads pooled across all replicates, 
using SPP64. Raw sites from each replicate of a protein were compared using an 
irreproducible discovery rate65 (IDR) threshold of 0.02. The resulting number of sites 
passing this IDR threshold was then used to filter the pooled sites of a protein. The set of 
sites were further filtered for artefacts using a blacklist of genomic regions from the 
ENCODE Project Consortium. Sites from all sources for each protein, including ENCODE, 
were then combined. The complete set of 165 proteins employed in these analyses is 
presented in Supplementary Table 11. In addition, we obtained FOXA2 ChIP-seq sites that 
were previously identified in human liver39 and lifted their positions to hg19.
We obtained annotation data for five histone modifications (H3K4me1, H3K4me3, 
H3K27ac, H3K36me3, and H3K27me3) and CTCF binding assayed from ChIP experiments. 
We used data from 9 cell types from ENCODE10 (Gm12878, K562, Hepg2, Hsmm, Huvec, 
Nhek, Nhlf, h1Hesc, and Hmec); we also obtained raw ChIP data assayed in primary 
pancreatic islets14 and pre-mature and mature human adipose stromal cells66. We mapped 
reads to hg19 using BWA62, and used the resulting mapped reads from these 12 cell types as 
input to ChromHMM67. We assigned states based on the following chromatin signatures: 
active promoter (H3K4me3 and H3K27ac); strong enhancer 1 (H3K4me3, H3K27ac, and 
H3K4me1); strong enhancer 2 (H3K27ac and H3K4me1); weak enhancer (H3K4me1); 
poised promoter (H3K27me3, H3K4me3, and H3K4me1); repressed (H3K27me3); insulator 
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(CTCF); and transcription (H3K36me3). For each cell type, we pooled the three enhancer 
states into one enhancer category, and the two promoter states into one promoter category. 
We also identified long non-coding RNA data from the Human Body Map (UCSC genome 
browser) and from pancreatic islets68.
For each genomic annotation, we tested for overall enrichment of the posterior probability 
that overlapping variants in the 99% credible sets are driving distinct association signals 
(πC). We first calculated the mean posterior probability (mean πC) over the set of variants 
overlapping a given annotation. We then generated a null distribution of the mean posterior 
probability (mean πC) by: (i) shifting the genomic locations of binding sites a random 
distance within 100kb in either direction; (ii) recalculating the mean posterior probability for 
99% credible set variants overlapping shifted sites; and (iii) repeating this procedure 100,000 
times. We estimated the fold-enrichment of each overlap by calculating the expected null 
posterior probability, and dividing the observed probability by the expected probability. We 
calculated a p-value for the enrichment by the proportion of permutations for which the 
expected posterior probability of driving the association signal was greater than or equal to 
that observed. We considered cell type annotations to be significantly enriched if the p-value 
was less than 0.05/37 = 0.0014 (Bonferroni correction for 37 annotations). We considered 
TFBS annotations to be significantly enriched if the p-value was less than 0.05/165 = 
0.00030 (Bonferroni correction for 165 factors). We next partitioned binding sites into those 
that are “shared” with another factor (i.e. genomic interval intersects a site for at least one 
other factor), and those that are “unique”. We also partitioned binding sites based on overlap 
with islet enhancer elements. For each factor with significant enrichment across all credible 
sets (FOXA2), we applied the same enrichment analysis, but restricted to credible set 
variants for each distinct association signal, separately.
We assessed the evidence for intersection in FOXA2 ChIP-seq sites from islets14, HepG210, 
and liver39, genome-wide and overlapping credible set variants, using BEDtools69.
Motif analysis
We conducted recognition motif enhancement analyses for the set of FOXA2 ChIP-seq 
binding sites. First, we obtained repeat-masked genomic sequence underlying each site using 
the UCSC human genome browser. We scanned sequences for enrichment in these motifs 
using MEME-ChIP70, which uses up to 100bp surrounding the mid-point of each site. This 
resulted in 198 enriched motifs with E-value (expected number of hits) less than 0.05 
(Supplementary Table 16). We compared each motif to those known from JASPAR71, 
ENCODE10, and Homer72 using Tomtom73.
Second, we identified variants in FOXA2 ChIP-seq sites predicted to disrupt an enriched 
recognition motif by: (i) scanning a 25bp of sequence flanking each variant allele using 
FIMO74 (p<0.0001); and (ii) retaining variants in highly conserved positions (entropy less 
than 0.5). For the 12 variants at FOXA2-enriched signals disrupting at least one recognition 
motif (Table 3, Supplementary Table 14), we compared their posterior probabilities of 
driving the association (πC) with those for non-disrupting variants in FOXA2 ChIP-seq sites 
at the same signals using a two-sided Wilcoxon rank-sum test.
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Electrophoretic mobility shift assays
EMSA was performed using nuclear extracts from human HepG2 and EndoC-βH1 cells. 
HepG2 cells were the generous gift of the Ratcliffe laboratory75 and authenticated by 
genotyping in the MHC region. Endo-βH1 cells were obtained from Endocells and have 
been previously authenticated44. Both cell lines were tested and found negative for 
mycoplasma contamination. Nuclear extracts were incubated with 32P gamma-ATP end-
labeled double-stranded DNA probes (PerkinElmer, MA). The forward strand probe 
sequences used are presented in Supplementary Table 17.
For each lane of the EMSA, 5μg of nuclear extract was incubated with 100 fmol labeled 
probes in a 10ul binding reaction containing 10mM Tris-HCl pH7.5, 4% glycerol, 1mM 
MgCl2, 0.5mM EDTA, 0.5mM DTT, 50mM NaCl and 1μg poly(dI-dC). For competition 
assays unlabeled probe at 100-fold excess was added to the binding reaction before addition 
of labeled probes. For super-shift assays the nuclear extract was pre-incubated with 1μg 
antibody for 30 minutes on ice before the probe was added. The following antibodies were 
used: anti-NEUROD1 (sc-1084X, Santa Cruz Biotechnology, Texas), anti-PTF1A 
(sc-98612X, Santa Cruz Biotechnology, Texas), anti-HNF3B (FOXA2) (sc-6554X, Santa 
Cruz Biotechnology, Texas), anti-YY1 (sc281X, Santa Cruz Biotechnology, Texas), anti-
TAL1 (sc12984X, Santa Cruz Biotechnology, Texas), normal rabbit Ig (sc-2027, Santa Cruz 
Biotechnology, Texas), normal goat Ig (sc-2028, Santa Cruz Biotechnology, Texas).
Luciferase activity
We synthesised 224bp nucleotide sequences containing either the risk or protective allele of 
the MTNR1B enhancer sequence rs10830963 in either the forward or reverse orientation by 
GeneArt (Life Technologies). Complementary single-stranded oligos were then annealed 
and sub-cloned into the minimal promoter-driven luciferase vector pGL4.23 (Promega) 
using Nhel and Xhol. Isolated clones were verified by sequencing.
For luciferase assays, human liver HepG2 and human beta-cell EndoC-βH145 cells were 
counted and seeded into 24 well trays (Corning) at 1.5×105 (HepG2) or 1.4×105 (EndoC-
βH1) cells/well. Transfections were performed in triplicate with either Lipofectamine 2000 
(HepG2) or Fugene 6 (EndoC-βH1) as per manufacturer’s instructions. Cells were 
transfected with 700ng pGL4.23 DNA containing the protective or risk MTNR1B enhancer 
sequence in either the forward or reverse orientation, or an equivalent amount of empty 
vector DNA, plus 10ng pRL-SV40 DNA (Promega) as a transfection control, per well. Cells 
were lysed 48 hours post-transfection and analysed for Firefly and Renilla luciferase 
activities using the Dual Luciferase Assay System (Promega) as per manufacturer’s 
instructions, in half-volume 96 well tray format on an Enspire Multimode Plate Reader 
(Perkin Elmer). Firefly luciferase activity was normalised to Renilla luciferase activity for 
each well, and the results expressed as a mean normalised activity relative to empty vector-
transfected cells. All experiments were performed three times in triplicate. A two-sided 
unpaired t-test was used to compare luciferase activity between alleles.
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Mouse gene expression analysis
We obtained fold-changes in pancreatic islet gene expression in wild type compared to 
Foxa1/Foxa2-null mice47. We used ENSEMBL to map mouse genes to human orthologs. We 
filtered for human genes annotated as protein coding in GENCODE. This filtering resulted 
in 4,629 human protein coding genes for analysis.
First, we calculated the genomic interval spanned by the variants in each credible set. We 
expanded this interval for 500kb on either side, and identified the set of genes overlapping 
this region using BEDtools69. To account for syntenic differences in gene order between 
species, we retained only those genes that were: (a) on the same chromosome; and (b) in 
exactly the same relative order in both mouse and human genomes. At the GIPR locus, one 
of the genes was ordered differently and thus removed from the analysis. At two loci, 
KCNJ11 and HNF1A, at least one of the genes was located on a different part of the same 
chromosome, and at another locus, GCK, genes were located on different chromosomes. For 
these three loci, we retained only those genes that were at the same chromosomal location to 
the interval covered by the credible set for the association signal for that locus (by lifting 
over from hg19 to mouse build mm10). Second, for each distinct association signal, we 
identified the closest gene to the index variant using BEDtools69. We then partitioned 
distinct association signals into those with evidence for enriched FOXA2 binding (fold-
enrichment >1) and those without, counting each gene only once in a given group. For each 
analysis, we converted the fold-changes to percentages, and compared the percent change in 
expression using a one-sided Wilcoxon rank-sum test between genes in each partition and all 
4,629 protein coding genes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. FOX2A bound sites are a genomic marker of T2D risk variants
(A) Variants in ChIP-seq binding sites for 165 proteins were tested for enrichment of 
posterior probabilities compared to variants in shifted sites. Variants in FOXA2 ChIP-seq 
sites were significantly enriched (p<0.00030). (B) FOXA2 ChIP-seq sites were partitioned 
based on overlap with other genomic features. There was stronger enrichment in: (i) FOXA2 
sites overlapping a ChIP-seq site for another protein compared to unique sites; (ii) sites 
identified in primary islets compared to HepG2 or primary liver cells; and (iii) sites 
overlapping islet enhancers compared to those that did not (**p<0.00030; *p<0.05). (C) 
Gaulton et al. Page 27
Nat Genet. Author manuscript; available in PMC 2016 May 18.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Variants at each signal were tested for FOXA2 enrichment. Nineteen signals had greater 
enrichment than expected compared to shifted sites; at 15 signals this enrichment was 
nominally-significant (p<0.05). (D) FOXA2-bound variants disrupting recognition motifs 
have an increased probability of being causal.
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Figure 2. The lone variant in the 99% credible set at the MTNR1B locus affects FOXA2-bound 
enhancer activity
(A) The intronic variant, rs10830963, has 99.8% probability of driving the association signal 
at the MTRN1B locus. This variant overlaps a FOXA2 binding site, and the risk allele G is 
predicted to create a de novo recognition motif, which closely matches the NEUROD1 
consensus. (B) Electrophoretic mobility shift assay of a 25bp fragment surrounding both 
alleles in EndoC-βH1 cell extracts. Proteins were bound to both alleles. In the presence of a 
NEUROD1 antibody, only the risk allele band was super-shifted, and in the presence of an 
unlabelled NEUROD1 consensus probe, the signal was competed away. NE: nuclear extract. 
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(C, D) The 224bp sequence surrounding each allele was cloned into a luciferase reporter 
construct containing a minimal promoter and tested for luciferase activity in (C) EndoC-βH1 
and (D) HepG2 cells (n=3 for each cell type). Results are presented as mean ± standard 
error. The risk allele had significantly increased enhancer activity over the protective allele 
in both forward and reverse orientations in both cell types.
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